Read More

Independent Data Monitoring Committee Completed Its Prespecified Review Of Interim Safety Data In Phio Pharmaceuticals’s Phase 1B Trial Of Ph-762 For Advanced Melanoma, Recommending The Study To Continue Without Modification.

PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells. Decreasing the expression of PD-1 increases the capacity of T

PHIO